The DMD target: why the dystrophin gene is so difficult to drug
Duchenne Muscular Dystrophy is caused by loss-of-function mutations in the DMD gene — the second-largest human gene at over 2.2 million base pairs and 79 exons — which encodes a 427 kDa dystrophin protein. The sheer scale of the gene, combined with the diversity of patient mutations, makes DMD one of the most technically demanding targets in rare disease drug development. The disease affects approximately 1 in 3,500–6,000 live male births, with progressive skeletal muscle degeneration and cardiorespiratory failure as the inevitable clinical trajectory.
Frameshift deletions are the primary mutational driver, clustered in two hotspot regions: exons 1, 3, 4, 5, 8, 13, and 19 in the 5′ proximal region, and exons 42–45, 47, 48, and 50–53 in the mid-distal region. These deletions disrupt the open reading frame and abolish functional dystrophin expression. Dystrophin itself serves as a structural linker between intracellular actin filaments and the extracellular matrix via the dystrophin-glycoprotein complex (DGC). Without it, mechanical contraction causes sarcolemmal rupture, uncontrolled calcium influx, protease activation, and fiber necrosis — progressing over years to fibrosis and fat replacement.
A central therapeutic logic across the DMD pipeline is converting a DMD frameshift mutation into a Becker muscular dystrophy (BMD)-like in-frame deletion — producing a truncated but partially functional dystrophin. Patients with BMD-like deletions typically have a milder phenotype, making this the mechanistic rationale for exon-skipping strategies.
Secondary molecular targets appearing across the retrieved patent and literature dataset include utrophin (a dystrophin paralogue subject to compensatory upregulation), alpha7beta1 integrin (a modifier of muscle integrity), nNOS (neuronal nitric oxide synthase, displaced from the sarcolemma in DMD), PKC theta (implicated in inflammatory signaling), PDE5A (a cGMP pathway modulator affecting blood flow and muscle function), and the aryl hydrocarbon receptor (AHR, a regulator of utrophin expression). These secondary targets underpin the small molecule strategies discussed later in this article.
The DMD gene spans over 2.2 million base pairs and contains 79 exons, encoding a 427 kDa dystrophin protein. Frameshift deletions in two hotspot regions — exons 1–19 (5′ proximal) and exons 42–53 (mid-distal) — are the primary cause of Duchenne Muscular Dystrophy, which affects approximately 1 in 3,500–6,000 live male births.
ASOs and exon skipping: the most clinically advanced DMD modality
Antisense oligonucleotide-mediated exon skipping is the dominant therapeutic paradigm in the DMD drug pipeline, and the only modality with FDA-approved drugs in this dataset. ASOs hybridize to pre-mRNA splice sites or exonic splice enhancer (ESE) sequences, sterically blocking the spliceosome and causing specific exon exclusion to restore the reading frame. The largest cluster of retrieved results — spanning both patents and papers — addresses this approach.
Phosphorodiamidate morpholino oligomers (PMOs) are the principal chemistry class, distinguished by uncharged phosphorodiamidate linkages and a six-membered morpholino ring replacing the ribose sugar, conferring nuclease stability. Earlier-generation 2′-O-methyl phosphorothioate oligonucleotides are also described in retrieved results, as is tricyclo-DNA (tc-DNA), which appears in two retrieved patents as a distinct chemistry for enhanced CNS and systemic access.
“Eteplirsen (exon 51 skipping) received FDA conditional approval in 2016 — and golodirsen (exon 53 skipping) followed — representing the furthest-advanced clinical signals in the entire DMD drug pipeline dataset.”
Retrieved results address skipping of exons 44, 45, 50, 51, 52, and 53, corresponding to the major mutational hotspot regions. The dataset explicitly references eteplirsen (Exondys 51) and golodirsen (Vyondys 53) as approved drugs. Earlier clinical data cited in retrieved patent text includes PRO051 (intramuscular injection in four DMD patients showing exon 51-specific skipping without adverse effects, citing van Deutekom et al. 2007) and drisapersen, a 2′-O-methyl phosphorothioate that failed to demonstrate significant muscle function improvement in trials. According to the FDA, conditional approval pathways have been central to getting these first-generation ASOs to patients while longer-term efficacy data is gathered.
An important evolution beyond unconjugated PMOs is the development of cell-penetrating peptide (CPP)–PMO conjugates. Retrieved Sarepta Therapeutics patents (2023) and a Sutura Therapeutics patent (2023) describe CPP-PMO conjugates as an evolution with enhanced delivery to skeletal and cardiac muscle. Multi-exon skipping is another emerging direction: a retrieved patent from the University of Alberta describes DG9-PMO “block” mixtures targeting a 45–55 exon cluster, which would theoretically be applicable to a larger proportion of DMD patients than single-exon strategies. Research published via NIH-funded programs has consistently highlighted multi-exon skipping as a priority for expanding patient eligibility.
Explore the full DMD exon-skipping patent landscape — assignees, filing dates, and claim scope — in PatSnap Eureka.
Analyse DMD Patents in PatSnap Eureka →Antibody-oligonucleotide conjugates: the fastest-moving IP cluster
Antibody-oligonucleotide conjugates (AOCs) represent the highest-velocity emerging IP cluster in the DMD drug pipeline, with active filings from 2023 to 2025 signalling commercial recognition that unconjugated PMO delivery is insufficient for adequate muscle uptake. In this approach, a PMO payload is covalently linked to an anti-transferrin receptor 1 (TfR1) antibody or antigen-binding fragment to enable receptor-mediated muscle targeting and endocytosis.
Two companies have independently converged on TfR1 as the muscle-targeting receptor. Avidity Biosciences has filed at least six retrieved patents covering anti-TfR1-PMO conjugates for exon 44, 50, and 52 skipping across US, WO, CA, CN, and TW jurisdictions (2023–2025). The drug-to-antibody ratio (DAR) of approximately 4–8 per conjugate is described for exon 44 skipping. Dyne Therapeutics has filed complementary patents (2024–2025) describing anti-TfR1 Fab-ASO conjugates demonstrating exon 23 skipping in mdx mice, with functional endpoint improvements including run-wheel distance and hindlimb fatigue resistance versus unconjugated ASO.
Avidity Biosciences and Dyne Therapeutics have independently filed patents in 2023–2025 using anti-transferrin receptor 1 (TfR1) antibody fragments to deliver PMO or ASO payloads to muscle cells via receptor-mediated endocytosis, representing a convergent muscle-targeting strategy in the DMD antibody-oligonucleotide conjugate space.
Both Avidity Biosciences and Dyne Therapeutics have independently selected anti-TfR1 antibody fragments as the delivery vehicle for PMO/ASO payloads — a convergence that signals TfR1-mediated endocytosis is becoming the accepted mechanism for next-generation muscle-targeted oligonucleotide delivery in DMD. Early IP positioning in this format is actively contested across multiple jurisdictions.
Evidence for AOC approaches is predominantly patent-driven, with preclinical animal data embedded in patent specifications. No retrieved results report Phase 3 efficacy outcomes for AOC modalities — these approaches appear preclinical within this dataset. The 2023–2025 filing window nonetheless represents a significant acceleration relative to earlier exon-skipping IP, and freedom-to-operate analysis across exon 44, 50, and 52 targets will be essential for any new entrant in this space.
AAV microdystrophin gene therapy: engineering around a packaging problem
AAV-mediated microdystrophin gene therapy addresses the root cause of DMD — absent dystrophin protein — but faces a fundamental constraint: the full-length 14 kb dystrophin cDNA exceeds AAV’s approximately 5 kb packaging capacity, necessitating engineered truncations. Retrieved patents describe multiple microdystrophin designs retaining the N-terminal actin-binding domain, key spectrin-like repeats (SR), and the cysteine-rich/C-terminal domain, while deleting dispensable central rod domain repeats.
AAV8 and AAV9 serotypes are most frequently cited for systemic transduction, with muscle-specific promoters such as MCK driving expression. Retrieved data from Nationwide Children’s Hospital and REGENXBIO describe sarcolemmal microdystrophin expression restoration, fibrosis reduction, and improved contractile force in mdx mouse models at doses of 1×10¹⁴ GC/kg or higher for AAV8-RGX-DYS1. The ΔSR5-15 microdystrophin design — deleting spectrin-like repeats 5 through 15 — is noted to correctly localize to the sarcolemma in mdx models, a key functional validation criterion. According to the European Medicines Agency, gene therapies for rare neuromuscular diseases are subject to accelerated assessment pathways, reflecting unmet medical need.
Several second-generation differentiation strategies are visible in the 2024–2025 filing window. A retrieved Nationwide Children’s Hospital patent describes rAAV co-expressing microdystrophin and miR-29c (an anti-fibrotic microRNA), demonstrating additive improvements in specific force and eccentric contraction protection in mdx/utrn+/- mice compared to microdystrophin alone. A 2025 patent from Kate Therapeutics describes rAAV vectors encoding microdystrophin with miRNA binding sites that selectively suppress transgene expression in dorsal root ganglia (DRG) — addressing a safety concern associated with systemic AAV administration. A University of Washington patent (2024) describes a split-intein approach using dual or triple AAV vectors to reconstitute full-length or large truncated dystrophin via protein trans-splicing, potentially circumventing the packaging limit entirely.
In AAV microdystrophin gene therapy for Duchenne Muscular Dystrophy, the full-length 14 kb dystrophin cDNA exceeds AAV’s approximately 5 kb packaging capacity. REGENXBIO and Nationwide Children’s Hospital patents describe the ΔSR5-15 microdystrophin design — which correctly localizes to the sarcolemma in mdx mouse models — at systemic doses of 1×10¹⁴ GC/kg or higher for AAV8-RGX-DYS1.
Track REGENXBIO, Nationwide Children’s Hospital, and emerging gene therapy filers across jurisdictions with PatSnap Eureka.
Explore Gene Therapy Patents in PatSnap Eureka →Small molecules and genome editing: mutation-agnostic and early-stage
Small molecule approaches in the DMD pipeline target secondary pathways rather than dystrophin directly, offering a mutation-agnostic therapeutic rationale with potential for broad patient coverage. The retrieved dataset identifies several distinct mechanistic clusters, all predominantly at preclinical stage.
PDE5A inhibitors and the nNOS/cGMP axis
Two retrieved patents from the University of Iowa Research Foundation describe phosphodiesterase type 5A (PDE5A) inhibitors for improving muscle blood flow and reducing exercise-induced muscle damage in mdx mice via the cGMP/nNOS pathway. In DMD, nNOS is displaced from the sarcolemma, impairing exercise-induced vasodilation; PDE5A inhibition is proposed to restore cGMP signaling and improve functional blood flow in exercising dystrophic muscle.
Utrophin upregulators
Utrophin is a dystrophin paralogue subject to compensatory upregulation, making it an attractive mutation-independent target. A retrieved patent from the University of Pennsylvania describes HDAC inhibitors (trichostatin A, AR-42) and other post-transcriptional utrophin upregulators. A separate retrieved patent from Peptris Technologies describes atovaquone as an AHR (aryl hydrocarbon receptor) inhibitor capable of upregulating utrophin — a repurposing strategy given atovaquone’s existing clinical use as an antiparasitic agent.
Additional small molecule targets
- PKC theta inhibition: A retrieved paper from the University of Campinas identifies PKC theta as a novel inflammatory pathway target in DMD.
- Vasoactive intestinal peptide (VIP) analogues: A retrieved patent from Phase Biopharmaceuticals describes elastin-like peptide-VIP conjugates reducing fibrosis and improving eccentric contraction resistance in mdx muscle.
- Alpha7beta1 integrin modulators: A retrieved patent from the University of Nevada describes agents that increase alpha7beta1 integrin expression as a complementary muscle membrane stabilization strategy.
- ERR-gamma agonists: A retrieved patent describes estrogen-related receptor gamma (ERRγ) activators for muscle regeneration in DMD.
Genome editing approaches
Retrieved results include two distinct gene-editing approaches, both exclusively patent-driven with no embedded clinical data. Precision BioSciences patents describe engineered meganucleases with specificity for recognition sequences within the dystrophin gene. CRISPR Therapeutics AG has filed patents on CRISPR/Cas9-based ex vivo and in vivo editing of the dystrophin gene. Vertex Pharmaceuticals has filed patents describing Staphylococcus aureus Cas9 (SaCas9) paired with guide sequences targeting defined DMD exon regions. The intersection of Cas9-based DMD editing with tissue-specific delivery remains an unresolved technical and IP challenge, consistent with WIPO‘s observation that CRISPR-based therapeutic patents are among the most actively contested in the current IP landscape.
Small molecule approaches in the DMD pipeline include PDE5A inhibitors targeting the cGMP/nNOS axis, utrophin upregulators such as HDAC inhibitors and atovaquone (an AHR inhibitor from Peptris Technologies), PKC theta inhibitors, alpha7beta1 integrin modulators, and ERR-gamma agonists — all representing mutation-agnostic strategies with potential for broad patient coverage across DMD genotypes.
Assignee landscape and strategic implications for the DMD drug pipeline
Sarepta Therapeutics is the most frequently appearing commercial assignee in this dataset, with multiple patents covering exon 45, 51, 52, and 53 skipping compositions, PMO chemistry, CPP-PMO conjugates, and rAAV microdystrophin vectors — active filings spanning 2016–2025 across CN, IL, and BR jurisdictions. Developers pursuing exon-skipping will encounter significant freedom-to-operate challenges across multiple exon targets, particularly 44, 51, 52, and 53. PatSnap’s life sciences intelligence platform provides claim-level analysis to support FTO assessments across these contested spaces.
REGENXBIO Inc. dominates the microdystrophin gene therapy patent cluster, with filings across WO, CA, TW, US, and CN jurisdictions (2022–2026). The Research Institute at Nationwide Children’s Hospital holds multiple patents for AAV micro-dystrophin vectors with immune suppression co-administration strategies across SG, SA, CA, BR, and IN jurisdictions. The multi-vector full-length dystrophin approach (University of Washington, 2024) and the DRG de-targeting strategy (Kate Therapeutics, 2025) signal second-generation differentiation axes that may extend the patent lifecycle of this modality.
Genome editing assignees — CRISPR Therapeutics AG, Precision BioSciences, and Vertex Pharmaceuticals — appear predominantly with CN filings and no embedded clinical data, suggesting early-stage IP protection phases. The small molecule utrophin upregulation and pathway-targeted approaches (PDE5A, AHR, PKC theta) constitute a mutation-agnostic therapeutic niche that is currently less densely patented than ASO or gene therapy modalities in this dataset, representing a potential opportunity for academic-industry partnering or de novo IP development, particularly for combination use with exon-skipping agents. PatSnap’s patent analytics tools can help identify white-space opportunities within these secondary target spaces.
“Small molecule utrophin upregulation and pathway-targeted approaches constitute a mutation-agnostic therapeutic niche that is currently less densely patented than ASO or gene therapy modalities — representing a potential opportunity for academic-industry partnering or de novo IP development.”